# Forte Biosciences, Inc. (FBRX) — merger/definitive [announced]
Source: SEC API (secapi.ai) · situation sit_f2dd327169eb8c984caf · retrieved 2026-08-12T07:01:26.876Z

## Overview
Forte Biosciences, Inc. is a biopharmaceutical company developing FB102, a topical immunomodulator for autoimmune and inflammatory skin diseases including vitiligo and celiac disease.

argenx BV, through its subsidiary Avena Merger Sub Inc., commenced a tender offer on August 6, 2026 to acquire all outstanding shares of Forte Biosciences, Inc. at $77.00 per share in cash. The offer, which expires on August 26, 2026 (unless extended), is being made pursuant to an Agreement and Plan of Merger dated July 26, 2026. Following the tender offer, Purchaser will merge with and into Forte Biosciences pursuant to Section 251(h) of the Delaware General Corporation Law, with Forte Biosciences surviving as a wholly owned subsidiary of argenx BV. The Forte Biosciences Board of Directors unanimously recommends that stockholders accept the offer and tender their shares.

## Terms
- Counterparty: argenx BV · Consideration: cash · Premium: 41.0% · Price/share: $77

## Key dates
- Announced 2026-08-06 · Expiry 2026-08-26

## Timeline
- 2026-08-06 · SC 14D9 (0001140361-26-031507): SC 14D9 - Forte Biosciences, Inc. — *Forte Biosciences, Inc. is a biopharmaceutical company developing FB102, a topical immunomodulator for autoimmune and inflammatory skin diseases including vitiligo and celiac disease.* argenx BV, through its subsidiary Avena Merger Sub Inc., commenced a tender offer on August 6, 2026 to acquire all outstanding shares of Forte Biosciences, Inc. at $77.00 per share in cash. The offer, which expires on August 26, 2026 (unless extended), is being made pursuant to an Agreement and Plan of Merger dated July 26, 2026. Following the tender offer, Purchaser will merge with and into Forte Biosciences pursuant to Section 251(h) of the Delaware General Corporation Law, with Forte Biosciences surviving as a wholly owned subsidiary of argenx BV. The Forte Biosciences Board of Directors unanimously recommends that stockholders accept the offer and tender their shares.
  https://www.sec.gov/Archives/edgar/data/1419041/0001140361-26-031507.txt

## Citations
- 0001140361-26-031507 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126031507